Deal Watch: AbbVie Moves Into Microbiome, Synthetic Biology With Synlogic Partnership
Executive Summary
Mylan adds more than 900 over-the-counter and generic products to its portfolio with the $9.9bn acquisition of Meda. Astellas finalizes the pursuit of Ocata which it began last November.